This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2016 by MabVax Therapeutics, Inc.
Sponsor:
Collaborator:
SciQuus Oncology
Information provided by (Responsible Party):
MabVax Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02687230
First received: February 9, 2016
Last updated: June 13, 2017
Last verified: July 2016
  Purpose
Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.

Condition Intervention Phase
Pancreatic Carcinoma Tumors That Express CA19-9 Drug: MVT-2163 Drug: MVT-5873 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Resource links provided by NLM:


Further study details as provided by MabVax Therapeutics, Inc.:

Primary Outcome Measures:
  • Safety of MVT-2163 alone and in combination with MVT-5873 [ Time Frame: About 12 monhts ]
    Number of subjects with treatment-related adverse events as assessed by CTCAE v4.0 will be collected and compiled

  • Peak Plasma Concentration (Cmax) of MVT-2163 alone and in combination with MVT-5873 [ Time Frame: About 12 monhts ]
    Cmax of MVT-2163

  • Biodistribution of MVT-2163 alone and in combination with MVT-5873 [ Time Frame: About 12 monhts ]
    The biodistribution of MVT-2163 will be determined by measureing radiation exposure for key organs and tissues

  • Dose of MVT-5873 required for optimal tumor visualization when combined with a fixed dose of MVT-2163 [ Time Frame: About 12 monhts ]
    Three doses of MVT-5873 (0, 17, and 47 mg) will be combined with MVT-2163 in order to determine which dose results in the best PET imaging of tumor

  • Determine the optimal time interval between MVT-2163 dose administration and tumor PET imaging [ Time Frame: About 12 months ]
    Images will be taken on severel days over the first week to determine the optimal day for obtaining PET images

  • Area under the plasma concentration versus time curve (AUC) of MVT-2163 alone and in combination with MVT-5873 [ Time Frame: About 12 months ]
    AUC of MVT-2163

  • Half-life (T1/2) of MVT-2163 alone and in combination with MVT-5873 [ Time Frame: About 12 months ]
    Half-life (T1/2) of MVT-2163


Secondary Outcome Measures:
  • The ability of MVT-2163 to detect sites of disease (localized and metastatic) in pancreatic cancer and/or other CA19-9 positive malignancies [ Time Frame: About 12 months ]
    PET scans obtained with MVT-2163 will be compared with conventional imaging (CT/MRI) to determine if MVT-2163 based PET scans are capable of detection tumors seen with conventional methods

  • Radiation dosimetry estimates using quantitative MVT-2163 biodistribution uptake data [ Time Frame: About 12 months ]
    Bio-distribution data will be used to estimate the radiation exposure of key organs and tissues

  • MVT-2163 PET imaging results in comparison with varying levels of CA19-9 antigen expression by IHC [ Time Frame: About 12 months ]
    A determination will be made as to the effect of varying levels of CA19-9 antigen expression by tumor IHC on the quality of MVT-2163 PET imaging

  • MVT-2163 PET imaging results in comparison with circulating CA19-9 levels [ Time Frame: About 12 months ]
    A determination will be made as to the effect of circulating levels of CA19-9 on the quality of MVT-2163 PET imaging

  • Presence of anti-drug antibodies (ADA) using an MVT-5873 ADA assay [ Time Frame: About 12 months ]
    Subjects will be tested for the development of anti-drug antibodies (ADA) against MVT-5873


Estimated Enrollment: 28
Study Start Date: July 2016
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
Drug: MVT-2163
MVT-2163 is administered intravenously as a PET imaging agent
Other Name: 89Zr-DFO-HuMab-5B1
Experimental: Cohort 2
Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
Drug: MVT-2163
MVT-2163 is administered intravenously as a PET imaging agent
Other Name: 89Zr-DFO-HuMab-5B1
Drug: MVT-5873
MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
Other Name: HuMab-5B1
Experimental: Cohort 3
Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
Drug: MVT-2163
MVT-2163 is administered intravenously as a PET imaging agent
Other Name: 89Zr-DFO-HuMab-5B1
Drug: MVT-5873
MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
Other Name: HuMab-5B1

Detailed Description:

This is an open label, nonrandomized, dose-escalation trial of a fixed dose of MVT-2163 and varying antibody masses of MVT-5873. The study is designed to identify an optimal dose (total antibody mass) and optimal timing, for tumor imaging using PET scanning. This trial will include a dose escalation and an expansion phase. During the dose escalation portion of the study, a determination of the optimal time to perform PET imaging will be made. Following the identification of the "optimal" dose and timing, an 10 additional subjects will be imaged using the best dose and timing.

In each portion of the study subjects will have a screening visit and, no more than 28 days later, those who are eligible for the study will receive MVT-2163. Each cohort will have 3-6 subjects. Subjects in cohort 1 will be administered MVT-2163 alone on day 1. Subjects in cohorts 2 and 3 will receive MVT-5873 on day 1, followed approximately 10 minutes later by MVT-2163. Subjects will return for visits to the clinic on days 2, 4, and 7 for additional imaging and safety assessments. A follow-up visit will occur on day 28.

The study will also evaluate the tissue distribution and pharmacokinetics of MVT-2163 and, based on these data, the study will estimate the radiation dosimetry of MVT-2163. Safety assessments will be performed using ECGs, vital signs measurements, assessments of performance status, and clinical laboratory measurements.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed, informed consent
  • Histologically confirmed, locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) or other malignancies known to express CA19-9 positive malignancies
  • At least one lesion by CT or MRI ≥ 2 cm
  • ECOG performance status of 0 to 2
  • Absolute neutrophil count ≥1.50 x 109/L
  • Hemoglobin ≥ 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)
  • Platelet count >75,000/ mm3
  • AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then ≤5.0 x ULN
  • Total bilirubin <1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, <3x the upper limit of normal
  • Serum creatinine (serum or plasma) ≤ 1.5 x ULN or GFR>50 mL/min
  • Serum albumin > 3.0g/dL
  • Willingness to participate in collection of pharmacokinetic samples
  • Willingness to use adequate contraception throughout study and for a period of 90 days last dose of study drug

Exclusion Criteria:

  • Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Major surgery other than diagnostic surgery within 28 days
  • History of anaphylactic reaction to human, or humanized, antibody
  • Other on-going cancer therapy or investigational agents (except MVT-5873 )
  • Known history of HIV or Hepatitis C
  • Pregnant or currently breast-feeding
  • Psychiatric illness/social situations that would interfere with compliance with study requirements
  • Significant cardiovascular risk including, but not limited to, recent (within 28 days) coronary stenting or myocardial infarction within 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02687230

Contacts
Contact: Paul W Maffuid, PhD 858.259.9405 clinicaltrials@mabvax.com
Contact: John Gutheil, MD clinicaltrials@mabvax.com

Locations
United States, Arizona
Honor Health Research Institute Not yet recruiting
Scottsdale, Arizona, United States, 85258
Contact: Erkut Borazanci, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Lars Guenter Christian Lohrmann, MD         
Sponsors and Collaborators
MabVax Therapeutics, Inc.
SciQuus Oncology
Investigators
Study Director: Paul W Maffuid, PhD MabVax Therapeutic Holdings, Inc.
  More Information

Responsible Party: MabVax Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02687230     History of Changes
Other Study ID Numbers: MV-0815-CP-001.01
Study First Received: February 9, 2016
Last Updated: June 13, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on September 21, 2017